SER רווחיות מכירות לפי רווח גולמי Serina Therapeutics Inc

סמלים רשמיים של חברת Serina (SER)

Serina Therapeutics, Inc. (SER) attracts leading chemists by offering academic freedom in the development of polymer-based therapies for Parkinson's disease. Changes in gross profit margins illustrate the effectiveness of this strategy, where 37.60 shapes the current metric. An innovative approach to drug delivery strengthens brand trust, while proprietary extended-release technology protects the company from competitive pricing pressure.

רווחיות גולמית: serinatherapeutics.com (SER) עבור 28.03.2024 - 20.11.2026

פילוחים אנליטיים ודוחות נתונים של חברת Serina Therapeutics (SER)

- שווי מניות ותחזית קונצנזוס למחירים:
הערכת שווי פונדמנטלית:Serina Therapeutics, Inc.
מוצר סדרתי של serinatherapeutics.com

Gross margin is calculated as the ratio of the difference between total revenue and the cost of goods sold to sales volume, determining the efficiency of direct production. For Serina Therapeutics, Inc. (SER), this metric will become critical when bringing POZ platform-based neurotherapies to market, reflecting the profitability of Parkinson's disease drug development via the gross margin chart.